Stay updated with breaking news from Edwarde Walsh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The U.S. Food and Drug Administration approved Pfizer's respiratory syncytial virus vaccine on Wednesday. The vaccine, called ABRYSVO, is the second RSV vaccine for people older than 60 to be approved by the FDA.
Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
US, FDA, vaccine, ABRYSVO, RSV vaccine, vulnerable group
The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, RENOIR, demonstrating the RSV vaccine's efficacy, immunogenicity, and safety in adults 60 and older.
The Food and Drug Administration (FDA) has approved Pfizer’s vaccine, Abrysvo, which protects adults 60 and older from ...